[Virtual Webinar]IQVIA Japan 2020 Pharma Market Insights: Outlook to 2024

Date: Thursday, April 16, 2020
Time: 12:00-13:15
Speaker: 
Alan Thomas, Director, Thought Leadership, IQVIA Japan K.K.
Hosting Committees: 
Healthcare; Digital Health;
Medical Devices and Diagnostics; Pharmaceuticals;
​Regenerative Medicine and Bioscience
Member Fee: ¥0
Guest Fee: ¥0
Registration/Cancellation Deadline: Wednesday, April 15, (Noon)

SIGN UP

This event will be hosted as a webinar. Instructions for joining the virtual meeting will be sent to registered attendees after the above stated deadline.​

Structural shifts in Japan’s pharmaceutical market are challenging the status quo. Recent advancements in the development of breakthrough therapies are changing the way in which we treat diseases and catalyzing significant reform in government policy. Strategic opportunities—including in specialty and biologics—alongside investment in innovation and launch underline Japan’s position as the second-largest market for R&D-driven pharma companies.

However, continued pressure on healthcare spending is impacting both government policy and pharma-company strategy as a balance emerges to support patient access to newer, safer, more effective treatments. While companies that made the shift in strategy reap their rewards, those that did not are now reassessing their position.
 
Join this “must” event for the pharma industry at which Alan Thomas, Director of Thought Leadership at IQVIA Japan K.K., will discuss these and other issues impacting the Japan market today and in the years ahead.

John W. Carlson III, Chair
William Bishop, Yuko Kidoguchi, Takeo Morooka, Toshio Nagase, R. Byron Sigel, Mika Shirai Vice Chairs
ACCJ Healthcare Committee

NOTE 1: This event is OFF THE RECORD.

NOTE 2: Please note that as with all guest presentations, the content and comments of the speakers reflects their own opinions and do not necessarily represent the opinions or policies of the ACCJ.

NOTE 3: ACCJ is aware of emerging concerns regarding use of Zoom and is following best practices to mitigate issues while evaluating other technology solutions.